scholarly article | Q13442814 |
P356 | DOI | 10.1002/EJI.200526124 |
P698 | PubMed publication ID | 15909311 |
P50 | author | Thomas M Kündig | Q105045997 |
P2093 | author name string | Kent A Smith | |
Adrian Bot | |||
Pål Johansen | |||
Tazio Storni | |||
Barbara R von Beust | |||
P2860 | cites work | MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4 | Q22009943 |
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene | Q22299417 | ||
A Toll-like receptor recognizes bacterial DNA | Q24290668 | ||
CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma | Q24568172 | ||
CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. | Q33647526 | ||
Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice | Q34006411 | ||
Toll meets bacterial CpG-DNA. | Q34260232 | ||
CpG motifs in bacterial DNA trigger direct B-cell activation | Q34307394 | ||
CpG motifs in bacterial DNA and their immune effects | Q34542287 | ||
Immunotherapeutic uses of CpG oligodeoxynucleotides | Q35730784 | ||
Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration | Q38345478 | ||
Lymphokine production by human T cells in disease states | Q40661109 | ||
Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles | Q40745968 | ||
CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses | Q40776605 | ||
High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo | Q41007804 | ||
Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects | Q45698211 | ||
International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? | Q53284971 | ||
CpG-DNA upregulates the major acute-phase proteins SAA and SAP. | Q54021251 | ||
H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies | Q73129213 | ||
Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins | Q73420690 | ||
CpG DNA induces stronger immune responses with less toxicity than other adjuvants | Q73502903 | ||
CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants | Q73814892 | ||
CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses | Q74027097 | ||
P433 | issue | 6 | |
P304 | page(s) | 1869-1876 | |
P577 | publication date | 2005-06-01 | |
P1433 | published in | European Journal of Immunology | Q5412727 |
P1476 | title | Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration | |
P478 | volume | 35 |
Q43601291 | A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors |
Q36496104 | A review of CpGs and their relevance to aquaculture |
Q38912244 | Allergen immunotherapy: routes, safety, efficacy, and mode of action |
Q27687250 | Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases |
Q83575548 | Antitumor activity mediated by CpG: the route of administration is critical |
Q89944637 | Autoantigen Treatment in Type 1 Diabetes: Unsolved Questions on How to Select Autoantigen and Administration Route |
Q47841051 | Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides |
Q35229225 | In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles |
Q36970017 | Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial |
Q35155423 | Intralymphatic immunotherapy |
Q35389863 | Intralymphatic immunotherapy and vaccination in mice |
Q35224136 | Liposome-encapsulated CpG enhances antitumor activity accompanying the changing of lymphocyte populations in tumor via intratumoral administration |
Q37374278 | Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. |
Q99711516 | Multifactorial Design of a Supramolecular Peptide Anti-IL-17 Vaccine Toward the Treatment of Psoriasis |
Q93116271 | NIR-light-mediated spatially selective triggering of anti-tumor immunity via upconversion nanoparticle-based immunodevices |
Q88143332 | Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma |
Q92343873 | Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases |
Q37700490 | Optimized systemic dosing with CpG DNA enhances dendritic cell-mediated rejection of a poorly immunogenic mammary tumor in BALB/c mice |
Q41526077 | Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity |
Q33519555 | Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice |
Q27335400 | Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice |
Q80625739 | Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do |